Invesco Ltd. Purchases New Position in Metsera Inc. $MTSR

Invesco Ltd. purchased a new stake in Metsera Inc. (NASDAQ:MTSR) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 9,974 shares of the company’s stock, valued at approximately $271,000.

Other institutional investors have also bought and sold shares of the company. New York State Common Retirement Fund acquired a new stake in Metsera in the 1st quarter valued at $131,000. Deutsche Bank AG acquired a new stake in Metsera in the 1st quarter valued at $374,000. Bank of New York Mellon Corp acquired a new stake in Metsera in the 1st quarter valued at $884,000. TD Asset Management Inc acquired a new stake in Metsera in the 1st quarter valued at $2,091,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Metsera in the 1st quarter valued at $3,410,000.

Metsera Stock Down 1.2%

Shares of MTSR opened at $35.87 on Monday. Metsera Inc. has a 12-month low of $12.30 and a 12-month high of $47.40. The stock’s fifty day simple moving average is $34.73 and its 200-day simple moving average is $28.63.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Wells Fargo & Company assumed coverage on Metsera in a research note on Friday, June 20th. They issued an “overweight” rating and a $65.00 price target on the stock. Bank of America boosted their price objective on Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Wall Street Zen lowered Metsera from a “hold” rating to a “sell” rating in a research note on Sunday. Guggenheim boosted their price objective on Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, June 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Metsera in a research note on Wednesday, September 3rd. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $59.00.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.